medigraphic.com
Archivos de Medicina (Manizales)

2022, Number 1

<< Back Next >>

Arch Med 2022; 22 (1)

Clinical and sociodemographic features of HIV-infected patients and immune reconstitution inflammatory syndrome in Antioquia (Colombia)

Gallego QS, Patiño IAM, Florez RDL, Benjumea BD, Sanchez IP, Villegas AE, Giraldo HS, Botero GJ, Taborda VN, Alzate ÁJC

Language: Spanish
References: 21
Page: 46-56
PDF size: 409.77 Kb.


ABSTRACT

Background: despite combined antiretroviral therapy (cART) effectiveness for the control of HIV infection, 15-30% of these patients develop Immune Reconstitution Inflammatory Syndrome (IRIS), consisting in a clinical worsening at the beginning cART. It is important to know the prevalence and characteristics of people with IRIS to generate prevention strategies. Objective: to describe the prevalence and sociodemographic characteristics of patients with IRIS HIV-related, from a health care facility in Antioquia - Colombia. Methods: in a population of 515 patients that started cART between 2013-2018, we developed a cross-sectional study with a simple random sampling of 188 HIV patients. The presence of IRIS was defined according to French criteria or high suspected IRIS in those who had insufficient clinical information and have developed an opportunistic infection (OI) after cART initiation. Results: the prevalence of IRIS was 12.8% (12.5% by French criteria and 87.5% by high suspected IRIS). IRIS patients were 25% women, median age 41.5 years. 87.5% presented OI. From these, the most common was tuberculosis disease (72.7%). Conclusions: in the era of cART, there are still an important number of IRIS cases, which indicates the need to continue implementing preventive and diagnostic protocols and early treatment initiation.


REFERENCES

  1. Joint United Nations Program on HIV/AIDS (UNAIDS). UNAIDS data 2020. Unaids. Geneva, Switzerland; 2020.

  2. Cuenta de Alto Costo [CAC]. Situación del VIH/SIDA en Colombia 2020. Bogotá, Colombia; 2020.

  3. Angulo-Rodríguez YJ. En la infección por VIH, ¿es mejor prevenir que curar? . Medicas UIS. 2015;28(2):183–185.

  4. Ochoa R. VIH/SIDA y desarrollo. Revista Cubana de Hiegiene y Epidemiología. 2004 May;42(2).

  5. Programa Conjunto de las Naciones unidas sobre VIH/SIDA. Estrategia 90-90-90 Un ambicioso objetivo detratamiento para contribuir al fin de la epidemia de sida. Onusida. 2013;39.

  6. Fondo Colombiano de Enfermedades de Alto Costo Cuenta de Alto Costo [CAC]. Situación del VIH Sida enColombia. Bogotá, Colombia: Fondo Colombiano de Enfermedades de Alto Costo; 2018. 1–161 p.

  7. Maartens G, Celum C, Lewin SR. HIV infection: Epidemiology, pathogenesis, treatment, and prevention.Lancet. 2014;384:258–271. DOI: 10.1016/S0140-6736(14)60164-1

  8. Bernal F. Farmacología De Los Antirretrovirales. Rev Médica Clínica Las Condes. 2016;27(5):682–697.DOI: 10.1016/j.rmclc.2016.09.013

  9. Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, et al. Antiretroviral Drugs for Treatmentand Prevention of HIV Infection in Adults : 2018 Recommendations of the International Antiviral Society– USA Panel. J Am Med Assoc. 2019;320(4):379–396. DOI: 10.1001/jama.2018.8431.Antiretroviral

  10. Osorio J, Álvarez D, Barreto-Mora J, Casanova-Bermeo M, Vargas-Plazas H, Giraldo-Bahamon G, et al. Infeccionespulmonares en pacientes con VIH 20 años después de la terapia antirretroviral combinada. ¿quéha cambiado? Infectio. 2016;20(3):180–189. DOI: 10.1016/j.infect.2015.08.002

  11. Zheng Y, Zhou H, He Y, Chen Z, He B, He M, et al. The Immune Pathogenesis of Immune ReconstitutionInflammatory Syndrome Associated with Highly Active Antiretroviral Therapy in AIDS. AIDS Res HumRetroviruses. 2014;30(12):1197–1202. DOI: 10.1089/aid.2014.0106

  12. Hidrón A, González Á. Síndrome inflamatorio de reconstitución inmune en pacientes infectados con elvirus de la inmunodeficiencia humana y afecciones fúngicas. Infectio. 2012;16(Supl 3):51–58.DOI: 10.1016/S0123-9392(12)70027-9

  13. Sereti I. Immune reconstruction inflammatory syndrome in HIV infection: beyond what meets the eye. TopAntivir Med. 2020;27(4):106–111.

  14. Müller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Incidence and Lethality of Immune ReconstitutionDisease in HIV-Infected Patients Starting Antiretroviral Therapy: Systematic Review and Meta-Analysis. Lancet Infect Dis. 2010;10(4):251–261. DOI: 10.1016/S1473-3099(10)70026-8.Incidence

  15. Nelson AM, Manabe YC, Lucas SB. Immune Reconstitution Inflammatory Syndrome (IRIS): What pathologistsshould know. Semin Diagn Pathol. 2017;34(4):340–351.

  16. Ministerio de Salud y Protección Social. Guía de práctica clínica (GPC) basada en la evidencia científica parala atención de la infección por VIH / Sida en adolescentes (con 13 años de edad o más) y adultos. Ministeriode Salud y Protección Social; 2014. 499 p.

  17. French MA, Price P, Stone SF. Immune Restoration Disease after Antiretroviral Therapy. AIDS.2004;18(12):1615–1627. DOI: 10.1097/01.aids.0000131375.21070.06

  18. Pelaez-Gil MC, Villalobos-Mora C, Mora-Hernandez G. Síndrome de Reconstitución Inmune. Med Leg CostaRica. 2017;34(1):1-6.

  19. Ratnam I, Chiu C, Kandala N-B, Easterbrook PJ. Incidence and Risk Factors for Immune ReconstitutionInflammatory Syndrome in an Ethnically Diverse HIV Type 1-Infected Cohort. Clin Infect Dis. 2006Feb;42(3):418–427. DOI: 10.1086/499356

  20. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White AC, et al. Incidence and risk factorsfor immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. Aids.2005;19(4):399–406. DOI: 10.1097/01.aids.0000161769.06158.8a

  21. Rateni L, Lupo S, Palazzi J, Racca L, Ghersevich S. Assessing Endocrine and Immune Parameters in HumanImmunodeficiency Virus-Infected Patients Before and After the Immune Reconstitution InflammatorySyndrome. Arch Endocrinol Metab. 2018;62(1):64–71. DOI: 10.20945/2359-3997000000010




2020     |     www.medigraphic.com